For citations:
Kornietskaya АL, Evdokimova SF, Bolotina LV, Rodionov EO, Fedenko AA. Efficacy and safety of lorlatinib as first-line treatment for advanced ALK-mutated non-small cell lung cancer: A clinical case study. Meditsinskiy sovet = Medical Council. 2024;(21):24-29. (In Russ.) https://doi.org/10.21518/ms2024-538